Unhappy Christmas: Roche suffered a double whammy and its stock plummeted 7%

Source: U.S and Chinese drug sources Dec 23, 2014 Roche announced today that its Alzheimer drug gantenerumab was terminated in an early patient with a three-stage clinical mid-term analysis that showed no efficacy signal On the same day, kadcyla alone or in combination with perjeta, the HER2 dimer inhibitor, did not prolong progression free survival more effectively than Herceptin plus chemotherapy in patients with advanced HER2 positive breast cancer As a result of this double blow, Roche's stock plummeted 7% today, and the market value of $15 billion was wiped out In September this year, perjeta joined Herceptin to set a survival record for advanced breast cancer, and kadcyla is a promising ADC product, which plays an important role in the whole ADC research and development field Today's experiment not only greatly reduced kadcyla's peak sales, people will question ADC as a strategy Obviously chemotherapy is still one of the pillars of the treatment of advanced breast cancer In addition, this result is a Christmas gift for the development enterprises of Herceptin Otherwise, if the standard therapy is changed to perjeta + kadcyla, those Herceptin biosimilars will hang their own southeast branch Gantenerumab is a powdery protein antibody Unlike the failed Pfizer's bapineuzumab and Lilly's solanezumab, gantenerumab removes the deposited powdery protein, while Bapi and sola remove the dissolved powdery protein Biib037, another powdery protein antibody that caused a great sensation recently, cleared the oligomeric powdery protein and entered the third phase of clinical practice with high profile two weeks ago Powdery protein theory is the core theory of Alzheimer's disease, but so far there is no drug to clear powdery protein to improve cognitive function The hypothesis behind the failure of Bapi and sola is that earlier use of drugs is more likely to see efficacy, but it is worrying that today's failed experiment is aimed at such patients Lilly's last solanezumab phase III clinic seems to be in a bad situation Roche, especially its gene tech, has always been a master of R & D, but its field other than anti-cancer is not very successful In recent years, he has lost a lot in large-scale gambling, including aleglitazar, a double PPAR agonist, and bitopterin, a schizophrenic drug Of course, Alzheimer's disease is equivalent to Mount Everest 100 years ago Whether someone can conquer it is still unknown Whether it can pass through the powdery protein path is even more questionable In fact, many large-scale drugs have similar experiences before they succeed Of course, more failed drugs have the same experience In this case, making correct judgment is the most necessary skill for new drug development